Related Experiment Video
Updated: Jun 4, 2026

07:46
Gait Analysis of Age-dependent Motor Impairments in Mice with Neurodegeneration
Published on: June 18, 2018
Gait disturbances in dystrophic hamsters
Thomas G Hampton1, Ajit Kale, Ivo Amende
1Mouse Specifics, Inc., Boston, MA 02109, USA. science@mousespecifics.com
Journal of Biomedicine & Biotechnology
|February 15, 2011
Summary
Delta-sarcoglycan-deficient hamsters exhibit gait abnormalities, mimicking human muscular dystrophy. Early detection of these walking deficits in this animal model can accelerate therapeutic development for muscular dystrophy.
Area of Science:
- Animal Models
- Biomechanical Analysis
- Neuromuscular Disorders
Background:
- The delta-sarcoglycan-deficient hamster is a valuable model for studying muscular dystrophy.
- Gait disturbances, a key clinical feature of muscular dystrophy, have not been previously characterized in this animal model.
Purpose of the Study:
- To quantitatively analyze gait in delta-sarcoglycan-deficient hamsters using ventral plane videography.
- To establish the validity of this animal model for recapitulating human muscular dystrophy gait impairments.
Main Methods:
- Ventral plane videography (DigiGait) was employed to capture and analyze hamster locomotion on a transparent treadmill.
- Gait parameters including stride length, propulsion, braking duration, and hindpaw eversion were measured in dystrophic (TO-2) and control (F1B) hamsters.
Main Results:
- Dystrophic TO-2 hamsters showed significantly shorter stride length, reduced hindlimb propulsion, delayed braking duration, and increased hindpaw eversion compared to controls.
- Gait disturbances were evident as early as 1 month of age and exacerbated by incline/decline walking.
- These findings demonstrate functional similarities to human muscular dystrophy gait deficits.
Conclusions:
- Quantitative gait analysis confirms that dystrophic TO-2 hamsters effectively model key aspects of human muscular dystrophy.
- Early identification of gait abnormalities in this model can expedite the development of novel muscular dystrophy therapies.

